Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Shanghai Pharma Signs MOU to Develop BIOCAD's mAb Portfolio in China

publication date: Sep 12, 2018

Shanghai Pharmaceuticals has signed a Memorandum of Understanding with BIOCAD, Russia's largest biotech company, to form JVs that manufacture and develop BIOCAD's biologic drugs for the China market. BIOCAD plans to include at least six of its novel biologics and biosimilar drugs for cancer and immunology in the agreements. One of the JVs will include a mAb manufacturing facility. BIOCAD says it has signed export contracts worth over $850 million in the last few years, supplying its biologic medications to 14 countries. More details....

Stock Symbol: (SHA: 601607)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.